Details of the Drug

General Information of Drug (ID: DMC7XDN)

Drug Name
Alprazolam
Synonyms
Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1], [2]
Epilepsy 8A60-8A68 Phase 2 [3]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 308.8
Topological Polar Surface Area (xlogp) 2.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 12-22 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.8 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 84-91% [4]
Clearance
The clearance of drug is 0.90 +/- 0.21 mL/min/kg [6]
Elimination
Alprazolam is mainly eliminated in the urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 6.3 - 26.9 hours (in healthy patients) [7]
Metabolism
The drug is metabolized via various CYPs including CYP3A4, CYP3A5, CYP3A7, and CYP2C9 [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4636 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.29% [9]
Vd
The volume of distribution (Vd) of drug is 0.8-1.3 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.073 mg/mL [5]
Chemical Identifiers
Formula
C17H13ClN4
IUPAC Name
8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Canonical SMILES
CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
InChI
InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
InChIKey
VREFGVBLTWBCJP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2118
ChEBI ID
CHEBI:2611
CAS Number
28981-97-7
DrugBank ID
DB00404
TTD ID
D0L9GG
VARIDT ID
DR01197
INTEDE ID
DR0075
ACDINA ID
D00024

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Translocator protein (TSPO) TTPTXIN TSPO_HUMAN Agonist [10], [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anxiety disorder
ICD Disease Classification 6B00-6B0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Translocator protein (TSPO) DTT TSPO 3.93E-10 0.43 1.02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Alprazolam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Alprazolam due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [50]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Alprazolam caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Arn-509 DMT81LZ Moderate Increased metabolism of Alprazolam caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Alprazolam and Oliceridine. Acute pain [MG31] [53]
Emapalumab DMZG5WL Moderate Altered metabolism of Alprazolam due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [52]
Siltuximab DMGEATB Moderate Altered metabolism of Alprazolam due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [52]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Alprazolam caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [54]
Voriconazole DMAOL2S Major Decreased metabolism of Alprazolam caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [55]
Posaconazole DMUL5EW Major Decreased metabolism of Alprazolam caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [56]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Alprazolam caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Alprazolam caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Alprazolam caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Alprazolam caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Erdafitinib DMI782S Moderate Increased metabolism of Alprazolam caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [59]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Alprazolam caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Tucatinib DMBESUA Moderate Decreased metabolism of Alprazolam caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Alprazolam and Dihydrocodeine. Chronic pain [MG30] [61]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Alprazolam and Olopatadine. Conjunctiva disorder [9A60] [62]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Alprazolam and Propofol. Corneal disease [9A76-9A78] [63]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Alprazolam and Alfentanil. Corneal disease [9A76-9A78] [53]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Alprazolam and Remifentanil. Corneal disease [9A76-9A78] [53]
Mifepristone DMGZQEF Moderate Decreased metabolism of Alprazolam caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [56]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Alprazolam caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [64]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Alprazolam and Ethanol. Cystitis [GC00] [65]
MK-8228 DMOB58Q Moderate Decreased metabolism of Alprazolam caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [66]
Aprepitant DM053KT Moderate Decreased metabolism of Alprazolam caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [67]
Sertraline DM0FB1J Minor Decreased metabolism of Alprazolam caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Alprazolam caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Alprazolam caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Alprazolam and Esketamine. Depression [6A70-6A7Z] [56]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Alprazolam due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [50]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Alprazolam caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Mephenytoin DM5UGDK Moderate Increased metabolism of Alprazolam caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Cenobamate DMGOVHA Moderate Increased metabolism of Alprazolam caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Stiripentol DMMSDOY Moderate Decreased metabolism of Alprazolam caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [74]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Alprazolam caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Rufinamide DMWE60C Moderate Increased metabolism of Alprazolam caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [52]
Ethotoin DMXWOCP Moderate Increased metabolism of Alprazolam caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Carbamazepine DMZOLBI Moderate Increased metabolism of Alprazolam caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [68]
Tazemetostat DMWP1BH Moderate Increased metabolism of Alprazolam caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Itraconazole DMCR1MV Major Decreased metabolism of Alprazolam caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Miconazole DMPMYE8 Moderate Decreased metabolism of Alprazolam caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Ketoconazole DMPZI3Q Major Decreased metabolism of Alprazolam caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Cimetidine DMH61ZB Moderate Decreased metabolism of Alprazolam caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [76]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Alprazolam and Brimonidine. Glaucoma [9C61] [77]
Boceprevir DMBSHMF Moderate Decreased metabolism of Alprazolam caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [78]
Telaprevir DMMRV29 Moderate Decreased metabolism of Alprazolam caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [78]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Alprazolam caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [79]
Rifampin DMA8J1G Minor Increased metabolism of Alprazolam caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [80]
Rifapentine DMCHV4I Moderate Increased metabolism of Alprazolam caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [81]
Delavirdine DM3NF5G Major Decreased metabolism of Alprazolam caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Alprazolam caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Efavirenz DMC0GSJ Moderate Increased metabolism of Alprazolam caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Saquinavir DMG814N Moderate Decreased metabolism of Alprazolam caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Etravirine DMGV8QU Moderate Increased metabolism of Alprazolam caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Didanosine DMI2QPE Minor Altered absorption of Alprazolam due to GI dynamics variation caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [50]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Alprazolam caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Darunavir DMN3GCH Moderate Decreased metabolism of Alprazolam caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Ritonavir DMU764S Moderate Decreased metabolism of Alprazolam caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Conivaptan DM1V329 Moderate Decreased metabolism of Alprazolam caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [88]
Probenecid DMMFWOJ Minor Decreased metabolism of Alprazolam caused by Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [89]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Alprazolam caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [52]
Crizotinib DM4F29C Moderate Decreased metabolism of Alprazolam caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [90]
Brigatinib DM7W94S Moderate Increased metabolism of Alprazolam caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [91]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Alprazolam and Porfimer Sodium. Lung cancer [2C25] [92]
Ceritinib DMB920Z Moderate Decreased metabolism of Alprazolam caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [55]
PF-06463922 DMKM7EW Moderate Increased metabolism of Alprazolam caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [93]
Selpercatinib DMZR15V Moderate Decreased metabolism of Alprazolam caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [52]
Idelalisib DM602WT Moderate Decreased metabolism of Alprazolam caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [55]
IPI-145 DMWA24P Moderate Decreased metabolism of Alprazolam caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [94]
LGX818 DMNQXV8 Moderate Increased metabolism of Alprazolam caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [95]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Alprazolam caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Alprazolam and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [96]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Alprazolam and Lasmiditan. Migraine [8A80] [97]
Exjade DMHPRWG Moderate Decreased metabolism of Alprazolam caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [98]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Alprazolam and Flibanserin. Mood disorder [6A60-6E23] [99]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Alprazolam and Thalidomide. Multiple myeloma [2A83] [100]
Rifabutin DM1YBHK Minor Increased metabolism of Alprazolam caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [80]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Alprazolam caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [52]
Nilotinib DM7HXWT Moderate Decreased metabolism of Alprazolam caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [101]
Imatinib DM7RJXL Moderate Decreased metabolism of Alprazolam caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Dasatinib DMJV2EK Moderate Decreased metabolism of Alprazolam caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [103]
Modafinil DMYILBE Minor Increased metabolism of Alprazolam caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [104]
Droperidol DM0DXA8 Major Additive cardiorespiratory depression effects by the combination of Alprazolam and Droperidol. Nausea/vomiting [MD90] [105]
Teduglutide DMYOAKS Moderate Altered absorption of Alprazolam caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [106]
Entrectinib DMMPTLH Moderate Decreased metabolism of Alprazolam caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [107]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Alprazolam and Levomethadyl Acetate. Opioid use disorder [6C43] [61]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Alprazolam and Apraclonidine. Optic nerve disorder [9C40] [77]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Alprazolam caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [108]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Alprazolam and Pentazocine. Pain [MG30-MG3Z] [53]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Alprazolam and Dextropropoxyphene. Pain [MG30-MG3Z] [109]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Alprazolam and Butorphanol. Pain [MG30-MG3Z] [53]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Alprazolam and Oxymorphone. Pain [MG30-MG3Z] [53]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Alprazolam and Levorphanol. Pain [MG30-MG3Z] [53]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Alprazolam and Dezocine. Pain [MG30-MG3Z] [53]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Alprazolam and Nalbuphine. Pain [MG30-MG3Z] [53]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Alprazolam and Buprenorphine. Pain [MG30-MG3Z] [110]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Alprazolam and Hydrocodone. Pain [MG30-MG3Z] [53]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Alprazolam and Meperidine. Pain [MG30-MG3Z] [53]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Alprazolam and Oxycodone. Pain [MG30-MG3Z] [53]
Abametapir DM2RX0I Moderate Decreased metabolism of Alprazolam caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [111]
Lefamulin DME6G97 Moderate Decreased metabolism of Alprazolam caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [112]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Alprazolam caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [55]
Enzalutamide DMGL19D Moderate Increased metabolism of Alprazolam caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [113]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Alprazolam due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [52]
Ixekizumab DMXW92T Moderate Altered metabolism of Alprazolam due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [52]
Bosentan DMIOGBU Moderate Increased metabolism of Alprazolam caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [114]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Alprazolam and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [115]
Tocilizumab DM7J6OR Moderate Altered metabolism of Alprazolam due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Canakinumab DM8HLO5 Moderate Altered metabolism of Alprazolam due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Rilonacept DMGLUQS Moderate Altered metabolism of Alprazolam due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Golimumab DMHZV7X Moderate Altered metabolism of Alprazolam due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Sarilumab DMOGNXY Moderate Altered metabolism of Alprazolam due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Alprazolam and Fentanyl. Sensation disturbance [MB40] [53]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Alprazolam caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [116]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Alprazolam caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [52]
Larotrectinib DM26CQR Moderate Decreased metabolism of Alprazolam caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [56]
Armodafinil DMGB035 Minor Increased metabolism of Alprazolam caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [104]
LEE011 DMMX75K Moderate Decreased metabolism of Alprazolam caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [117]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Alprazolam caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [118]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Alprazolam and Tizanidine. Tonus and reflex abnormality [MB47] [119]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Alprazolam and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [115]
Amiodarone DMUTEX3 Minor Potentiate the pharmacologic effects by the combination of Alprazolam and Amiodarone. Ventricular tachyarrhythmia [BC71] [120]
⏷ Show the Full List of 123 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
D&C red no. 30 E00456 3000709 Colorant
Docusate sodium E00563 23673837 Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium silicate E00533 21910000 Adsorbent; Anticaking agent; Diluent; Opacifying agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Alprazolam 1 mg tablet 1 mg Oral Tablet Oral
Alprazolam 0.5 mg tablet 0.5 mg Oral Tablet Oral
Alprazolam 0.25 mg tablet 0.25 mg Disintegrating Oral Tablet Oral
Alprazolam 0.5 mg tablet 0.5 mg Disintegrating Oral Tablet Oral
Alprazolam 1 mg tablet 1 mg Disintegrating Oral Tablet Oral
Alprazolam 2 mg tablet 2 mg Disintegrating Oral Tablet Oral
Alprazolam 3 mg tablet 3 mg 24 HR Extended Release Tablet Oral
Alprazolam 0.25 mg tablet 0.25 mg Oral Tablet Oral
Alprazolam 2 mg tablet 2 mg Oral Tablet Oral
Alprazolam 3 mg tablet 3 mg 24 HR Extended Release Oral Tablet Oral
Alprazolam 1 mg tablet 1 mg 24 HR Extended Release Oral Tablet Oral
Alprazolam 1 mg tablet 1 mg 24 HR Extended Release Tablet Oral
Alprazolam 2 mg tablet 2 mg 24 HR Extended Release Oral Tablet Oral
Alprazolam 2 mg tablet 2 mg 24 HR Extended Release Tablet Oral
Alprazolam 0.5 mg tablet 0.5 mg 24 HR Extended Release Oral Tablet Oral
Alprazolam 0.5 mg tablet 0.5 mg 24 HR Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7111).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074046.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA Approved Drug Products: XANAX XR (alprazolam) extended-release tablets
5 BDDCS applied to over 900 drugs
6 Yarker YE, Goa KL, Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007.
7 FDA Approved Drug Products: XANAX (alprazolam) tablets
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
11 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
12 No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
15 Drug Interactions Flockhart Table
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
25 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
26 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
35 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
36 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
37 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
38 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
39 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
40 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
41 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
42 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
43 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
44 Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
45 Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
48 Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
49 New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
50 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
51 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
54 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
55 Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
56 Cerner Multum, Inc. "Australian Product Information.".
57 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
58 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
59 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
60 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
61 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
62 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
63 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
64 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
65 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
66 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
67 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
68 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
69 Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS "Fluoxetine impairs clearance of alprazolam but not of clonazepam." Clin Pharmacol Ther 52 (1992): 479-86. [PMID: 1424422]
70 Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
71 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
72 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
73 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
74 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
75 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
76 Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI "Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam." Psychopharmacology (Berl) 80 (1983): 275-8. [PMID: 6137021]
77 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
78 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
79 Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
80 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
81 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
82 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
83 Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
84 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
85 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
86 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
87 Greenblatt DJ, vonMoltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI "Alprazolam-ritonavir interaction: Implications for product labeling." Clin Pharmacol Ther 67 (2000): 335-41. [PMID: 10801241]
88 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
89 Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
90 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
92 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
93 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
95 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
96 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
97 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
98 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
100 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
101 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
102 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
103 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
104 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
105 Canadian Pharmacists Association.
106 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
107 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
108 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
109 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
110 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
111 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
112 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
113 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
114 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
115 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
116 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
117 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
118 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
119 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
120 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]